Planet Biotechnology
Biotechnology, Clawiter Rd, Hayward, , 94545, California, 25571, United States, 1-10 Employees
Who is PLANET BIOTECHNOLOGY
Planet Biotechnology produced the first plant-made antibody, or plantibody, ever tested in a clinical trial. We are focused on discovering, developing and commercializing new antibody-bas...
Read More
-
Headquarters: 25571 Clawiter Rd, Hayward, California, 94545, United States
-
Date Founded: 1998
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
-
CEO:
Elliott Fineman
Email
Phone
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from PLANET BIOTECHNOLOGY
Planet Biotechnology Org Chart and Mapping
Similar Companies to Planet Biotechnology
Mozza Foods
-
1-10
-
$ 10 Million to 25 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Planet Biotechnology
Answer: Planet Biotechnology's headquarters are located at Clawiter Rd, Hayward, , 94545, California, 25571, United States
Answer: Planet Biotechnology's official website is https://planetbiotechnology.com
Answer: Planet Biotechnology's revenue is $1 Million to $5 Million
Answer: Planet Biotechnology's SIC: 2834
Answer: Planet Biotechnology's NAICS: 325412
Answer: Planet Biotechnology has 1-10 employees
Answer: Planet Biotechnology is in Biotechnology
Answer: Planet Biotechnology top competitors include: Mozza Foods
Answer: Planet Biotechnology contact info: Phone number: Website: https://planetbiotechnology.com
Answer: Planet Biotechnology produced the first plant-made antibody, or plantibody, ever tested in a clinical trial. We are focused on discovering, developing and commercializing new antibody-based therapeutic and preventative products through cultivation of genetically modified green plants to meet significant underserved medical needs. Scientists at Planet Biotechnology identify and develop promising antibodies and receptor-antibody fusion molecules for the treatment and prevention of infectious diseases including emerging diseases and bio-threat agents. We routinely adapt our antibody and receptor-antibody products for rapid production in non-food, non-feed green plants grown in greenhouses. This same approach has been used by others to produce three anti-Ebola virus antibodies that are undergoing clinical trials in Africa.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month